NASDAQ:ACET Adicet Bio Q3 2026 Earnings Date & Estimates $3.94 -0.05 (-1.25%) Closing price 04:00 PM EasternExtended Trading$3.93 -0.01 (-0.36%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adicet Bio is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call DateNovember 5, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Adicet Bio in Q3 2026Adicet Bio is expected to post earnings of -$1.56 per share. In the same quarter a year earlier Adicet Bio reported -$4.64 per share. Adicet Bio last reported on August 5, 2026, posting -$1.99 per share and missing the -$1.69 consensus estimate. Adicet Bio has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.56Prior-Year EPS-$4.64Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.99 (Missed by -$0.30)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Adicet Bio Q3 2026 Earnings FAQ When does Adicet Bio report Q3 2026 earnings? Adicet Bio (NASDAQ:ACET) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Adicet Bio's Q3 2026 earnings call? Adicet Bio's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Adicet Bio? Analysts expect Adicet Bio to post earnings of -$1.56 per share for Q3 2026. Adicet Bio Earnings HeadlinesAdicet Bio, Inc. (ACET) - What Are Researchers Saying About This Stock?October 18, 2026 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street ZenOctober 17, 2026 | americanbankingnews.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 26 at 1:00 AM | Banyan Hill Publishing (Ad)Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Adicet Bio (ACET)September 30, 2026 | theglobeandmail.comAdicet Bio reports positive Prula-cel phase 1 lupus data as pivotal study plans advanceSeptember 28, 2026 | msn.comAdicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis TranscriptSeptember 28, 2026 | seekingalpha.comSee More Adicet Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email. Email Address About Adicet BioAdicet Bio (NASDAQ:ACET) is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development. Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity. Its lead programs have included ADI-001, an investigational allogeneic gamma delta CAR T-cell therapy targeting CD19 for certain B-cell malignancies, including relapsed or refractory large B-cell lymphoma. The company has also pursued additional candidates aimed at hematologic cancers and solid tumors. Founded in 2014 and headquartered in Redwood City, California, Adicet Bio has advanced its programs through collaborations and clinical development activities in the United States and internationally. The company is led by Chief Executive Officer Chen Schor. Its therapies remain investigational and are subject to clinical testing and regulatory review.View Adicet Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
